newsfilter
← Latest News
PR Newswire·

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome

NEW YORK, Aug. 5, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it signed a memorandum of understanding ("MOU") wi